The synergy and complementarities of the partner groups:
The TTA consortium is formed by strong research groups with complementary expertise located in different hospital divisions and teamed up with external national and international collaborators. The administrative head will be supported by a 50% coordinator to ensure that all planned activities are performed at top quality level. By regular meetings, seminars and joint supervision of postdocs and PhD students, the consortium will coordinate its activities through a steering committee of participating partners and facilitate collaborative proposals for additional external funding including Nordic collaboration and EU-grant applications.
We have a recommendation from head of division (the Department of Microbiology (MIK), The Division of Laboratory Medicine (KLM):
Why is this initiative given priority? Why is this research initiative of strategic importance for the clinical core activities of the hospital?
The rapid emergence of resistant bacteria is occurring worldwide, endangering the efficacy of antibiotics. Many decades after the first patients were treated with antibiotics, bacterial infections have again become a threat. The problem requires urgent effort in developing new knowledge in this field as a basis for providing faster and more specific diagnostic tools, enhanced surveillance, and new antibiotics to the clinical setting. During the last years, OUS has experienced a significant increase in antimicrobial resistant bacteria leading to increased patient morbidity in line with global trends. Thus, emergence of resistant bacteria has a direct impact on clinical core activities in the hospital. How is this research initiative linked to specific clinical tasks or obligations of the hospital on the national or regional level? As the largest university hospital in Norway, we have a special responsibility to provide knowledge and support research in the most challenging fields of medicine, and to make our large clinical material available for research in collaboration with our patients. This initiative will enable our hospital to fulfill these obligations in the field of antimicrobial resistance.
Does the division plan to stimulate this research activity? In what way? The division KLM enables research in this area by providing infrastructure and key personnel as part of the existing organization